[go: up one dir, main page]

FR13C0013I1 - - Google Patents

Info

Publication number
FR13C0013I1
FR13C0013I1 FR13C0013C FR13C0013I1 FR 13C0013 I1 FR13C0013 I1 FR 13C0013I1 FR 13C0013 C FR13C0013 C FR 13C0013C FR 13C0013 I1 FR13C0013 I1 FR 13C0013I1
Authority
FR
France
Prior art keywords
glucagon
analogs
peptide
synthesis
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0013I1 publication Critical patent/FR13C0013I1/fr
Application granted granted Critical
Publication of FR13C0013I2 publication Critical patent/FR13C0013I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR13C0013C 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon Active FR13C0013I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12
PCT/CA1997/000252 WO1997039031A1 (fr) 1996-04-12 1997-04-11 Analogues de peptide 2 du type glucagon

Publications (2)

Publication Number Publication Date
FR13C0013I1 true FR13C0013I1 (fr) 2013-05-04
FR13C0013I2 FR13C0013I2 (fr) 2013-08-16

Family

ID=24530501

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0013C Active FR13C0013I2 (fr) 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon

Country Status (16)

Country Link
EP (5) EP1231219B1 (fr)
JP (3) JP4148994B2 (fr)
CN (1) CN1268640C (fr)
AT (2) ATE227309T1 (fr)
AU (1) AU733857B2 (fr)
BR (1) BRPI9708566B8 (fr)
CA (1) CA2251576C (fr)
DE (2) DE69716905T2 (fr)
DK (2) DK0906338T3 (fr)
ES (2) ES2188929T3 (fr)
FR (1) FR13C0013I2 (fr)
HK (3) HK1033324A1 (fr)
LU (1) LU92153I2 (fr)
NZ (1) NZ332281A (fr)
PT (2) PT906338E (fr)
WO (1) WO1997039031A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
EP1231219B1 (fr) * 1996-04-12 2010-08-25 1149336 Ontario Inc. Peptide-2 analogue au glucanon
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (fr) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methodes pour ameliorer le fonctionnement du gros intestin
DE69819488T2 (de) * 1997-05-16 2004-08-26 1149336 Ontario Inc., Toronto Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
WO1999043361A1 (fr) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
WO1999058144A1 (fr) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Procedes d'amelioration du fonctionnement du gros intestin
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
WO2005019262A1 (fr) * 2003-08-21 2005-03-03 Novo Nordisk A/S Purification de peptides apparentes au glucagon
JP4874811B2 (ja) 2004-01-21 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ペプチドのトランスグルタミナーゼ媒介性の結合
WO2006050244A2 (fr) 2004-11-01 2006-05-11 Nps Allelix Corp. Traitement de patients atteints du syndrome de l'intestin court avec colon en continuite
ES2361095T5 (es) 2005-05-04 2021-11-23 Zealand Pharma As Análogos del péptido 2 tipo glucagón (GLP-2)
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (fr) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 en utilisation pour la récupération intestinale et musculaire
EP2314616A1 (fr) * 2009-10-23 2011-04-27 Ferring B.V. Agonistes peptidiques de GLP-2
WO2011052523A1 (fr) * 2009-10-30 2011-05-05 大塚化学株式会社 Forme glycosylée d'analogue du glp-1 antigénique
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
JP2013526535A (ja) * 2010-05-11 2013-06-24 エヌピーエス ファーマシューティカルズ インコーポレイテッド 腎機能障害または肝機能障害の治療または予防のための方法
WO2012131109A2 (fr) 2011-04-01 2012-10-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Peptides et compositions pharmaceutiques utilisés dans un traitement par voie nasale, destiné à des patients atteints d'anxiété et de troubles du sommeil
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2018069442A1 (fr) * 2016-10-12 2018-04-19 University Of Copenhagen Agonistes doubles peptidiques de gipr et glp2r
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (fr) 2018-07-23 2020-01-30 Zealand Pharma A/S Utilisations thérapeutiques d'agonistes de glp-2
EP3628683A1 (fr) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations d'analogues de peptide-2 de type glucagon (glp-2)
EP3628682A1 (fr) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations d'analogues glucagon-like-peptide-2 (glp-2)
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2021071837A1 (fr) 2019-10-07 2021-04-15 Kallyope, Inc. Agonistes de gpr119
JP2023516187A (ja) 2020-02-28 2023-04-18 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
EP4126004A1 (fr) 2020-03-30 2023-02-08 Zealand Pharma A/S Combinaison d'agonistes
CN118843639A (zh) * 2021-12-17 2024-10-25 白南生物技术有限公司 Gipr和glp2r的肽双重激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
EP0658568A1 (fr) 1993-12-09 1995-06-21 Eli Lilly And Company Peptides insulinotropes de type glucagon, compositions les contenant et méthode de préparation
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1997031943A1 (fr) 1996-03-01 1997-09-04 Novo Nordisk A/S Utilisation d'une composition pharmaceutique contenant un peptide visant a reduire l'appetit
EP1231219B1 (fr) * 1996-04-12 2010-08-25 1149336 Ontario Inc. Peptide-2 analogue au glucanon
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (fr) 2001-02-01 2002-08-29 Drucker Daniel J Renforcement de l'activite de glp-2

Also Published As

Publication number Publication date
BRPI9708566A (pt) 2000-01-04
HK1147761A1 (en) 2011-08-19
AU2500297A (en) 1997-11-07
EP2218734A2 (fr) 2010-08-18
JP4148994B2 (ja) 2008-09-10
EP1231219B1 (fr) 2010-08-25
EP0906338A1 (fr) 1999-04-07
HK1050204B (zh) 2011-09-23
NZ332281A (en) 2000-03-27
EP1231219A1 (fr) 2002-08-14
PT906338E (pt) 2003-03-31
LU92153I2 (fr) 2013-04-19
AU733857B2 (en) 2001-05-31
JP5019466B2 (ja) 2012-09-05
EP2218734B1 (fr) 2013-06-05
JP2007204491A (ja) 2007-08-16
JP4149497B2 (ja) 2008-09-10
EP0906338B1 (fr) 2002-11-06
JP2000511881A (ja) 2000-09-12
PT1231219E (pt) 2010-11-30
ATE478892T1 (de) 2010-09-15
CA2251576C (fr) 2012-08-21
BR9708566B1 (pt) 2012-09-04
HK1033324A1 (en) 2001-08-24
CA2251576A1 (fr) 1997-10-23
ES2188929T3 (es) 2003-07-01
DE69716905D1 (de) 2002-12-12
EP2009024A1 (fr) 2008-12-31
DK0906338T3 (da) 2003-03-03
CN1268640C (zh) 2006-08-09
JP2008184465A (ja) 2008-08-14
HK1050204A1 (en) 2003-06-13
WO1997039031A1 (fr) 1997-10-23
ES2351661T3 (es) 2011-02-09
FR13C0013I2 (fr) 2013-08-16
DE69716905T2 (de) 2003-07-24
CN1244872A (zh) 2000-02-16
BRPI9708566B8 (pt) 2022-01-18
ATE227309T1 (de) 2002-11-15
DK1231219T3 (da) 2010-12-20
EP2275438A1 (fr) 2011-01-19
EP2218734A3 (fr) 2010-10-13
DE60142885D1 (de) 2010-10-07

Similar Documents

Publication Publication Date Title
FR13C0013I1 (fr)
HUT64298A (en) Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
AU681198B2 (en) Preparation of 3,4,4-trisubstituted-piperidinyl-N- alkylcarboxylates and intermediates
EP0443449A3 (en) Process for the preparation of oxetanones
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
HU902288D0 (en) Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
AU7880494A (en) 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
EP0287066A3 (en) Process for continuous production of octa -2,7-dien-1-ol
MY106522A (en) Arylaminocarbonyl compounds.
DE59610819D1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
DE3070735D1 (en) 4-aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments
RU1833357C (ru) Cпocoб пoлучehия 2,6-ди-tpet-буtилфehoлa
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
AU8516991A (en) Arg a human gene related to but distinct from abl proto-oncogene
GB9100381D0 (en) Human bfgf derivatives,their analogs and process for their production
HU910463D0 (en) Process for the production of medical preparation
ZA911397B (en) N-cycloalkylalkylamines,their process of preparation,their use as a medicament and their synthesis intermediates
HUP9600476A3 (en) Benzothiophene compounds, intermediates, process for their production, their use and compositions containing them
AU619888C (en) Alpha, alpha - disubstituted n-cycloalkylalkylbenzylamines, process for their preparation, their use as a medicament and their synthesis intermediates
AU634635C (en) 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3- propanediols and related compounds, a process and intermediates for their preparation and their use as medicaments
YU16590A (en) Process for preparing cyclical derivatives of 2',3'-seco-uridine
UA6626A (uk) Кормова добавка для корів
ZA923165B (en) Novel anthelmintic milbemycin analogs of novel microorganisms
MN426A8 (en) Preparation of lactic-acidic product vitaminized by b12 using propion-acidic p.shermani bacteria